The breast cancer expert discussed 2 advances in HER2-positive breast cancer treatment that healthcare providers should look for.
Seattle Genetics announced the development after data was presented at the 2019 San Antonio Breast Cancer Symposium.
The cancer risk and prevention expert discussed germline testing and the benefits it lends to patients with breast cancer.
The assistant professor from the University of Michigan talked about personalizing radiation treatment in patients with breast cancer and how genomic signatures can be used to identify the radiation needs of patients.
The hematology and medical oncology expert described the implementation of biosimilars into treating patients with breast cancer.
The professor of radiation oncology discussed these tailored treatments for when patients receive neoadjuvant chemotherapy, and they get a complete pathologic response.
Five years of treatment with anastrozole safely and effectively prevented breast cancer recurrence in high-risk postmenopausal women at 10.9 years of follow-up.
Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer.
The addition of pertuzumab to the previous standard of trastuzumab plus chemotherapy as an adjuvant therapy for patients with operable HER2-positive early breast cancer continued to reduce the risk for recurrence and death during a 6-year updated analysis.
T-DXd demonstrated improved and durable response rates in heavily pretreated patients with advanced HER2-positive breast cancer.